Nicaragua: These 5 Drugs Face Patent Expirations and Generic Entry in 2024 - 2025

Generic name: simeprevir sodium
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: July 29, 2025
Generic Entry Controlled by: Nicaragua Patent 200,800,036

OLYSIO is a drug marketed by Janssen Prods. There are nine patents protecting this drug.

This drug has one hundred and thirty-nine patent family members in forty-three countries.

See drug price trends for OLYSIO.

The generic ingredient in OLYSIO is simeprevir sodium. There is one drug master file entry for this API. Additional details are available on the simeprevir sodium profile page.

Generic name: raltegravir potassium
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: December 03, 2024
Generic Entry Controlled by: Nicaragua Patent 200,700,138

ISENTRESS is a drug marketed by Msd Sub Merck. There are six patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and twenty-five patent family members in forty-five countries.

See drug price trends for ISENTRESS.

The generic ingredient in ISENTRESS is raltegravir potassium. There are five drug master file entries for this API. Nine suppliers are listed for this generic product. Additional details are available on the raltegravir potassium profile page.

Generic name: bupropion hydrobromide
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: June 27, 2025
Generic Entry Controlled by: Nicaragua Patent 201,000,015

APLENZIN is a drug marketed by Bausch. There are eight patents protecting this drug and three Paragraph IV challenges. One tentatively approved generic is ready to enter the market.

This drug has fifty-two patent family members in eighteen countries.

See drug price trends for APLENZIN.

The generic ingredient in APLENZIN is bupropion hydrobromide. There are thirty-eight drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the bupropion hydrobromide profile page.

Generic name: bupropion hydrobromide
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: June 27, 2025
Generic Entry Controlled by: Nicaragua Patent 201,000,044

APLENZIN is a drug marketed by Bausch. There are eight patents protecting this drug and three Paragraph IV challenges. One tentatively approved generic is ready to enter the market.

This drug has fifty-two patent family members in eighteen countries.

See drug price trends for APLENZIN.

The generic ingredient in APLENZIN is bupropion hydrobromide. There are thirty-eight drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the bupropion hydrobromide profile page.

Generic name: lorcaserin hydrochloride
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: December 21, 2024
Generic Entry Controlled by: Nicaragua Patent 200,700,160

BELVIQ is a drug marketed by One tentatively approved generic is ready to enter the market.

This drug has fifty-two patent family members in eighteen countries. There has been litigation on patents covering BELVIQ

See drug price trends for BELVIQ.

The generic ingredient in BELVIQ is lorcaserin hydrochloride. There are five drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the lorcaserin hydrochloride profile page.

Generic name: lamivudine; raltegravir potassium
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: December 03, 2024
Generic Entry Controlled by: Nicaragua Patent 200,700,138

DUTREBIS is a drug marketed by Merck Sharp Dohme. There are two patents protecting this drug.

This drug has ninety-five patent family members in forty-three countries.

The generic ingredient in DUTREBIS is lamivudine; raltegravir potassium. There are twenty-nine drug master file entries for this API. Additional details are available on the lamivudine; raltegravir potassium profile page.

Generic name: dacomitinib
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: May 06, 2024
Generic Entry Controlled by: Nicaragua Patent 200,600,262

VIZIMPRO is a drug marketed by Pfizer. There are four patents protecting this drug.

This drug has ninety-three patent family members in forty-eight countries.

See drug price trends for VIZIMPRO.

The generic ingredient in VIZIMPRO is dacomitinib. Two suppliers are listed for this generic product. Additional details are available on the dacomitinib profile page.